| Merck (Schweiz) AG - Rebif 8.8 und 22 RebiDose, Injektionslösung im Fertigpen | | 62067 | | 01 | | Rebif 8.8 und 22 RebiDose | | Injektionslösung im Fertigpen | | L03AB07 | | Interferon beta-1a | | 13.02.2012 | | |
| | Composition | | I) 8.8 mcg/0.2 ml: interferonum beta-1a ADNr 8.8 µg corresp. 2.4 Mio U.I., alcohol benzylicus 1.0 mg, mannitolum, methioninum, poloxamerum 188, natrii acetas trihydricus, natrii hydroxidum, acidum aceticum, aqua ad iniectabile q.s. ad solutionem pro 0.2 ml corresp. natrium 0.01 mg.
II) 22 mcg / 0.5 ml: interferonum beta-1a ADNr 22 µg corresp. 6 Mio U.I., alcohol benzylicus 2.5 mg, mannitolum, methioninum, poloxamerum 188, natrii acetas trihydricus, natrii hydroxidum, acidum aceticum, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium max. 0.03 mg. | | Packungsbestandteile | | I | | | Injektionslösung im Fertigpen | | | | | | | | Principe actif | Concentr. |
|---|
| Interferonum Beta-1a Adnr | 8.8µg / 0.2ml |
| | BAG: Principe actif | Concentr. |
|---|
| Interferonum Beta-1a Adnr | 22 mcg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Acide Acétique | | | Alcohol Benzylicus | 1mg / 0.2ml | | Mannitol | | | Methionine | | | Natrii Acetas Trihydricus | | | Sodium Hydroxide | | | Poloxamer | 188 |
| |
| II | | | Injektionslösung im Fertigpen | | | | | | | | Principe actif | Concentr. |
|---|
| Interferonum Beta-1a Adnr | 22µg / 0.5ml |
| | BAG: Principe actif | Concentr. |
|---|
| Interferonum Beta-1a Adnr | 22 mcg |
| | | | Agents auxilliaires | Concentr. |
|---|
| Acide Acétique | | | Alcohol Benzylicus | 2.5mg / 0.5ml | | Mannitol | | | Methionine | | | Natrii Acetas Trihydricus | | | Sodium Hydroxide | | | Poloxamer | 188 |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | 6 seringue(s) | 599.44 | 668.35 | B | LS | Non |
|
|
